Adaptate

About Adaptate

Adaptate Biotherapeutics, accessible at adaptatebiotx.com, is a pioneering immunotherapy company focused on developing therapeutic antibodies. These antibodies are designed to modulate the activity of gamma delta T cells, a type of immune cell that plays a crucial role in the body's defense against diseases. The company operates in the biopharmaceutical market, specifically targeting the development of novel therapies for serious diseases such as cancer and autoimmune disorders.

Adaptate Biotherapeutics primarily serves patients who suffer from severe health conditions that require advanced treatment options. Their clients also include healthcare providers and institutions that administer these therapies. The company spun out from GammaDelta Therapeutics in late 2019 and has since received significant investment from notable entities like Abingworth and Takeda Pharmaceutical Company Limited.

The business model of Adaptate Biotherapeutics revolves around research and development (R&D) of innovative immunotherapies. They operate a state-of-the-art laboratory facility in London, where a team of scientists and researchers work on advancing these novel therapies. The company generates revenue through partnerships, investments, and potentially through the commercialization of their therapeutic products once they receive regulatory approval.

Adaptate Biotherapeutics makes money by attracting investments from pharmaceutical companies and venture capital firms interested in cutting-edge immunotherapy research. Additionally, they may earn revenue through licensing agreements, where other companies pay for the rights to use their developed therapies, and through direct sales of their approved treatments.

In summary, Adaptate Biotherapeutics is at the forefront of immunotherapy, developing therapeutic antibodies to treat serious diseases by modulating gamma delta T cells. They serve patients, healthcare providers, and institutions, operating within the biopharmaceutical market. Their business model focuses on R&D, partnerships, and commercialization of their therapies.